SPRY: ARS Pharmaceuticals, Inc.
Performance
SPRY -64.41%
Watchlist
Select an item
Summary
SPRY at a glance
SPRY returned -64.41% over the past year and -18.55% a year over five years. Its worst drop in that year was -79.71%, smaller than 2% of stocks on Redstone, and its Sharpe ratio of -1.03 beats 4% of stocks on Redstone. It pays no dividends.
Current Drawdown
-75.88%
Rolling Volatility
88.31%
Actions
Metrics
Risk Indicators
Alpha-95.84%
Beta1.81x
Sharpe-1.03
Sortino-1.40
Omega0.84
Calmar-0.81
Martin-1.82
Profile
About SPRY
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $313M
- Employees
- 200
- Headquarters
- San Diego, CA
- Website
- ars-pharma.com
Comparisons